Tetraphase Pharmaceuticals Inc. (TTPH)

1.20
0.03 2.44
NASDAQ : Health Technology
Prev Close 1.23
Open 1.24
Day Low/High 1.18 / 1.25
52 Wk Low/High 1.01 / 4.49
Volume 754.04K
Avg Volume 723.20K
Exchange NASDAQ
Shares Outstanding 53.74M
Market Cap 69.87M
EPS -1.40
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Tetraphase Pharmaceuticals To Present Data On Preclinical Activity Of TP-2846 In Acute Myeloid Leukemia

Tetraphase Pharmaceuticals To Present Data On Preclinical Activity Of TP-2846 In Acute Myeloid Leukemia

Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a biopharmaceutical company focused on developing and commercializing novel tetracyclines to treat life-threatening conditions, today announced it will present three posters on TP-2846, the Company's newly...

First Week Of August 16th Options Trading For Tetraphase Pharmaceuticals (TTPH)

First Week Of August 16th Options Trading For Tetraphase Pharmaceuticals (TTPH)

Investors in Tetraphase Pharmaceuticals, Inc saw new options begin trading this week, for the August 16th expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 224 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

EQUITY NOTICE: Rosen Law Firm Announces Filing Of Securities Class Action Lawsuit Against Tetraphase Pharmaceuticals, Inc. - TTPH

EQUITY NOTICE: Rosen Law Firm Announces Filing Of Securities Class Action Lawsuit Against Tetraphase Pharmaceuticals, Inc. - TTPH

Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Tetraphase Pharmaceuticals, Inc.

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Tetraphase Pharmaceuticals, Inc. To Contact The Firm

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Tetraphase Pharmaceuticals, Inc. To Contact The Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Tetraphase Pharmaceuticals, Inc.

Interesting TTPH Call Options For October 19th

Interesting TTPH Call Options For October 19th

Investors in Tetraphase Pharmaceuticals, Inc saw new options begin trading this week, for the October 19th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the TTPH options chain for the new October 19th contracts and identified the following call contract of particular interest.

Robbins Geller Rudman & Dowd LLP Announces A Securities Case Has Been Filed On Behalf Of Purchasers Of Tetraphase Pharmaceuticals, Inc. Securities

Robbins Geller Rudman & Dowd LLP Announces A Securities Case Has Been Filed On Behalf Of Purchasers Of Tetraphase Pharmaceuticals, Inc. Securities

Robbins Geller Rudman & Dowd LLP announces that a securities class action case was filed on behalf of purchasers of Tetraphase Pharmaceuticals, Inc.

IMPORTANT INVESTOR NOTICE: The Schall Law Firm Announces The Filing Of A Class Action Lawsuit Against Tetraphase Pharmaceuticals, Inc. And Encourages Investors With Losses In Excess Of $100,000 To Contact The Firm

IMPORTANT INVESTOR NOTICE: The Schall Law Firm Announces The Filing Of A Class Action Lawsuit Against Tetraphase Pharmaceuticals, Inc. And Encourages Investors With Losses In Excess Of $100,000 To Contact The Firm

The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Tetraphase Pharmaceuticals, Inc.

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Tetraphase Pharmaceuticals, Inc. To Contact The Firm

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Tetraphase Pharmaceuticals, Inc. To Contact The Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Tetraphase Pharmaceuticals, Inc.

First Week Of November 16th Options Trading For Tetraphase Pharmaceuticals (TTPH)

Investors in Tetraphase Pharmaceuticals, Inc saw new options become available this week, for the November 16th expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 197 days until expiration the newly available contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

INVESTOR ALERT: Investigation Of Tetraphase Pharmaceuticals Announced By Holzer & Holzer

INVESTOR ALERT: Investigation Of Tetraphase Pharmaceuticals Announced By Holzer & Holzer

Holzer & Holzer, LLC is investigating whether Tetraphase Pharmaceuticals, Inc.

First Week of August 17th Options Trading For Tetraphase Pharmaceuticals (TTPH)

First Week of August 17th Options Trading For Tetraphase Pharmaceuticals (TTPH)

Investors in Tetraphase Pharmaceuticals, Inc saw new options become available this week, for the August 17th expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 225 days until expiration the newly available contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Interesting TTPH Call Options For January 2018

Interesting TTPH Call Options For January 2018

Investors in Tetraphase Pharmaceuticals, Inc saw new options begin trading this week, for the January 2018 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the TTPH options chain for the new January 2018 contracts and identified the following call contract of particular interest.

RSI Alert: Tetraphase Pharmaceuticals (TTPH) Now Oversold

RSI Alert: Tetraphase Pharmaceuticals (TTPH) Now Oversold

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Tetraphase Pharmaceuticals Presents Clinical Data From Oral Eravacycline Development Program At IDWeek 2017

Tetraphase Pharmaceuticals Presents Clinical Data From Oral Eravacycline Development Program At IDWeek 2017

- Company plans to advance current oral eravacycline formulation into a phase 2 study in 1H18 -

TheStreet Quant Rating: D (Sell)